Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session

ConferenceSacituzumab TirumotecanPositive

AI Analysis

Summary

Multiple Phase III clinical studies of sacituzumab tirumotecan (sac-TMT) have been selected as late-breaking abstracts for presentation at the 2026 ESMO Congress in Madrid, with OptiTROP-Lung04 and OptiTROP-Lung06 to be presented in the lung cancer session.

Clinical Trial Data

Phase

Phase III

Outcome Details

Multiple Phase III studies selected as late-breaking abstracts (LBAs) for presentation at ESMO 2026

Importance:6/10

Sentiment:

0.60

TROP2 ADClate-breaking abstractlung cancerESMO conferencePhase III

Related Companies

$DFPH $MDCE $CHHE

Read the original article

Published by PR Newswire Clinical Trials on September 22, 2026 7:40 AM

Read Original